-
741
-
742
Genetic association between immune-mediated inflammatory diseases and peripheral artery disease: a Mendelian randomization study
Published 2025-01-01Subjects: Get full text
Article -
743
Clinical Features and Prognosis of Double-Positive Anti-MDA5 and Anti-CCP Antibodies in Dermatomyositis: A Retrospective Study
Published 2025-02-01Subjects: Get full text
Article -
744
Do cytokines play a role in the transition from acute to chronic musculoskeletal pain?
Published 2025-02-01Subjects: “…Rheumathoid arthritis…”
Get full text
Article -
745
-
746
-
747
Can the adherence to quality of care indicators for early rheumatoid arthritis in clinical practice reduce risk of hospitalisation?...
Published 2020-09-01“…Objective To describe the adherence to quality of care indicators in early rheumatoid arthritis (RA) and to evaluate its impact on the risk of hospitalisation in a real-world setting.Design Retrospective cohort study.Setting Patients with early-onset RA identified from healthcare regional administrative databases by means of a validated algorithm between 2006 and 2012 in the Lombardy region (Italy).Participants The study cohort included 14 203 early-onset RA (71% female, mean age 60 years).Outcome measures For each patient, a summary adherence score was calculated starting from the compliance to six quality indicators: (1–2) methotrexate or sulfasalazine or leflunomide with/without glucocorticoids, (3–4) other disease-modifying antirheumatic drugs (DMARDs) with/without glucocorticoids, (5) early interruption of glucocorticoids, (6) early clinical assessment.The relationship between low, intermediate and high categories of the summary score and the 12-month risk of hospitalisation for all causes and for RA was assessed.Results During a follow-up of 1 year, 2609 hospitalisations occurred, of which 704 were for RA (main or secondary diagnosis) and 252 primarily for RA. …”
Get full text
Article -
748
The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)
Published 2015-01-01“…Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program. …”
Get full text
Article -
749
The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2
Published 2025-02-01Subjects: “…difficult-to-treat rheumatoid arthritis…”
Get full text
Article -
750
Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
Published 2025-01-01Subjects: Get full text
Article -
751
Anxiety and depression in childhood rheumatologic conditions: A topical review
Published 2021-01-01Subjects: Get full text
Article -
752
Methyl Canthin-6-one-2-carboxylate Inhibits the Activation of the NLRP3 Inflammasome in Synovial Macrophages by Upregulating Nrf2 Expression
Published 2025-01-01Subjects: Get full text
Article -
753
Diagnostic Algorithm for Joint Pain in Patients with Inflammatory Bowel Disorders
Published 2022-01-01Subjects: Get full text
Article -
754
Clinical characteristics and prognosis of children with culture-negative osteoarticular infections: a meta-analysis based on cohort studies
Published 2025-01-01Subjects: Get full text
Article -
755
Effect observation and nursing of Tongbi exercise in relief of rheumatoid arthritis pain: A case report (通痹操缓解类风湿关节炎疼痛1例临床观察及护理)
Published 2021-12-01Subjects: “…rheumatoid arthritis…”
Get full text
Article -
756
Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23
Published 2020-01-01“…Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. …”
Get full text
Article -
757
-
758
Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report
Published 2019-01-01“…Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib. …”
Get full text
Article -
759
Is Intra-articular Platelet-rich Plasma Injection Safe and Effective in Osteoarthritis Knee? A Prospective Study: A Case Series
Published 2024-01-01Subjects: “…western ontario and mcmaster universities arthritis index score…”
Get full text
Article -
760
A meta-analysis and systematic review of the clinical efficacy and safety of platelet-rich plasma combined with hyaluronic acid (PRP + HA) versus PRP monotherapy for knee osteoarth...
Published 2025-01-01Subjects: “…Western ontario and McMaster universities arthritis index (WOMAC) total scores…”
Get full text
Article